Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma

R. G. Fairchild; J. A. Coderre; S. Packer; D. Greenberg; B. H. Laster

doi:10.1016/0360-3016(89)90448-3

Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma

R. G. Fairchild
, J. A. Coderre
, S. Packer
, D. Greenberg
, B. H. Laster

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Thiouracil (TU) selectively binds to the pigment melanin during melanogenesis and is rapidly cleared from normal tissues. This compound shows little affinity for pre-formed melanin. BALB/c mice, carrying the subcutaneously transplanted Harding-Passey melanoma, were given i.p. injections of ³⁵S-labeled thiouracil in a range of doses and administration schedules. Injected doses ranged from 1.3 to 10 mCi per mouse with resultant tumor dose rates of 10 to 30 cGy/hr, respectively. At the lower dose rates, growth delay of ∼1 to 2 weeks was observed in all tumors. At the highest doses used, complete tumor regression (no regrowth) was observed in some cases, with extended growth delays of ∼6 weeks in the rest. These results illustrate the possible utility of radiolabeled thiouracil as a systemically administered brachytherapy agent for melanoma.

Original language	English
Pages (from-to)	337-343
Number of pages	7
Journal	International journal of radiation oncology, biology, physics
Volume	17
Issue number	2
DOIs	https://doi.org/10.1016/0360-3016(89)90448-3
State	Published - 1 Jan 1989
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Brachytherapy
Harding-Passey melanoma
Thiouracil

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/0360-3016(89)90448-3

Cite this

@article{e9f73eb407504b79a11587c7bfbc5dd2,

title = "Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma",

abstract = "Thiouracil (TU) selectively binds to the pigment melanin during melanogenesis and is rapidly cleared from normal tissues. This compound shows little affinity for pre-formed melanin. BALB/c mice, carrying the subcutaneously transplanted Harding-Passey melanoma, were given i.p. injections of 35S-labeled thiouracil in a range of doses and administration schedules. Injected doses ranged from 1.3 to 10 mCi per mouse with resultant tumor dose rates of 10 to 30 cGy/hr, respectively. At the lower dose rates, growth delay of ∼1 to 2 weeks was observed in all tumors. At the highest doses used, complete tumor regression (no regrowth) was observed in some cases, with extended growth delays of ∼6 weeks in the rest. These results illustrate the possible utility of radiolabeled thiouracil as a systemically administered brachytherapy agent for melanoma.",

keywords = "Brachytherapy, Harding-Passey melanoma, Thiouracil",

author = "Fairchild, \{R. G.\} and Coderre, \{J. A.\} and S. Packer and D. Greenberg and Laster, \{B. H.\}",

year = "1989",

month = jan,

day = "1",

doi = "10.1016/0360-3016(89)90448-3",

language = "English",

volume = "17",

pages = "337--343",

journal = "International journal of radiation oncology, biology, physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma

AU - Fairchild, R. G.

AU - Coderre, J. A.

AU - Packer, S.

AU - Greenberg, D.

AU - Laster, B. H.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Thiouracil (TU) selectively binds to the pigment melanin during melanogenesis and is rapidly cleared from normal tissues. This compound shows little affinity for pre-formed melanin. BALB/c mice, carrying the subcutaneously transplanted Harding-Passey melanoma, were given i.p. injections of 35S-labeled thiouracil in a range of doses and administration schedules. Injected doses ranged from 1.3 to 10 mCi per mouse with resultant tumor dose rates of 10 to 30 cGy/hr, respectively. At the lower dose rates, growth delay of ∼1 to 2 weeks was observed in all tumors. At the highest doses used, complete tumor regression (no regrowth) was observed in some cases, with extended growth delays of ∼6 weeks in the rest. These results illustrate the possible utility of radiolabeled thiouracil as a systemically administered brachytherapy agent for melanoma.

AB - Thiouracil (TU) selectively binds to the pigment melanin during melanogenesis and is rapidly cleared from normal tissues. This compound shows little affinity for pre-formed melanin. BALB/c mice, carrying the subcutaneously transplanted Harding-Passey melanoma, were given i.p. injections of 35S-labeled thiouracil in a range of doses and administration schedules. Injected doses ranged from 1.3 to 10 mCi per mouse with resultant tumor dose rates of 10 to 30 cGy/hr, respectively. At the lower dose rates, growth delay of ∼1 to 2 weeks was observed in all tumors. At the highest doses used, complete tumor regression (no regrowth) was observed in some cases, with extended growth delays of ∼6 weeks in the rest. These results illustrate the possible utility of radiolabeled thiouracil as a systemically administered brachytherapy agent for melanoma.

KW - Brachytherapy

KW - Harding-Passey melanoma

KW - Thiouracil

UR - https://www.scopus.com/pages/publications/0024315223

U2 - 10.1016/0360-3016(89)90448-3

DO - 10.1016/0360-3016(89)90448-3

M3 - Article

C2 - 2753757

AN - SCOPUS:0024315223

SN - 0360-3016

VL - 17

SP - 337

EP - 343

JO - International journal of radiation oncology, biology, physics

JF - International journal of radiation oncology, biology, physics

IS - 2

ER -

Therapeutic effects of S-35-thiouracil in balb/c mice carrying harding-passey melanoma

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this